Last updated: February 25, 2026
What are the excipient components in KEPPRA formulations?
KEPPRA (Levetiracetam) primarily contains the active pharmaceutical ingredient (API) levetiracetam at doses of 500 mg, 750 mg, and 1000 mg. Its commercial formulations include immediate-release oral tablets, which are composed of excipients designed for stability, bioavailability, and manufacturability.
Common excipients in KEPPRA tablets:
- Microcrystalline cellulose (binder and filler)
- Croscarmellose sodium (disintegrant)
- Magnesium stearate (lubricant)
- Lactose monohydrate (filler)
- Silica colloidal anhydrous (flow enhancer)
How does excipient selection influence KEPPRA's formulation and patent portfolio?
Excipients impact shelf life, absorption rate, tolerability, and patentability. KEPPRA's patent filings focus on the API; however, formulation patents may cover specific excipient combinations—particularly novel disintegrants or controlled-release matrices.
Patent strategies often involve:
- Using excipients that improve bioavailability or reduce side effects
- Developing alternative excipient compositions to circumvent patent expiration
- Formulating controlled-release versions with modified excipient matrices
What are commercial opportunities related to excipient innovation?
-
Formulation patent extensions: Developing and patenting new excipient combinations or delivery systems can extend exclusivity. For example, alternative disintegrants or binders that enhance onset of action or improve tolerability.
-
Patent challenges and reformulations: Post-patent expiration, competitors may introduce generic versions with modified excipients to avoid patent infringement. Companies could develop "authenticated" formulations with patented excipient matrices for second-generation products.
-
Manufacturing efficiencies: Innovating excipient use to streamline production processes reduces costs, which can translate into competitive pricing positions or higher margins.
-
Alternative delivery systems: Extending KEPPRA's formulations through depot injections, ODTs, or transdermal patches utilizing excipients compatible with these modalities.
Market dynamics and competitive landscape
As of 2023, KEPPRA remains a leading antiepileptic medication, with global sales nearing USD 1.6 billion annually[1]. Patent expiry for specific KEPPRA formulations occurred in multiple jurisdictions between 2018 and 2022, opening markets for generics[2].
Generic manufacturers employ excipient modifications—such as substituting lactose with other fillers—to differentiate their products or address patient tolerability issues. Innovative excipient strategies can influence market share and patient adherence.
Regulatory considerations
Excipient use must comply with regulatory standards, ensuring inertness, stability, and safety. Changes in excipient composition often require abbreviated new drug application (ANDA) submissions, with bioequivalence demonstrations.
Regulators prioritize the characterization and safety profile of excipients. Innovations must balance patentability with compliance and safety.
Strategic recommendations
- Focus on patented excipient matrices that enhance bioavailability or tolerability.
- Invest in R&D to identify excipients that enable sustained-release formulations.
- Monitor patent expirations to plan formulation innovation.
- Collaborate with excipient manufacturers to access novel, proprietary excipients.
- Explore alternative delivery systems leveraging excipient advancements.
Key Takeaways
- KEPPRA formulations primarily utilize standard excipients, but innovation in excipient design offers extended patent life and market differentiation.
- Patent strategies involve unique excipient combinations and controlled-release matrices.
- Post-patent expiry opportunities include formulating with modified excipients for generics or improved branded products.
- Excipient innovations must meet regulatory standards and demonstrate clinical benefits.
- Market competition drives ongoing excipient reformulations, impacting cost, efficacy, and patient compliance.
FAQs
1. What excipients are critical for KEPPRA tablet stability?
Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and silica colloidal anhydrous primarily maintain stability and aid manufacturability.
2. Can excipient changes impact KEPPRA's bioavailability?
Yes. Modifying excipients can alter dissolution rates, affecting absorption, which requires regulatory bioequivalence studies.
3. Are there ongoing patents covering KEPPRA excipient formulations?
Most patents focus on the API; however, formulation-specific patents, including excipient combinations, may still be in effect or expiring soon.
4. How does excipient innovation extend KEPPRA's market exclusivity?
By developing novel formulations or delivery systems with proprietary excipients, a company can secure additional patent protection.
5. What are alternative delivery systems for KEPPRA?
Options include orally disintegrating tablets (ODTs), transdermal patches, or long-acting injectables, all requiring specialized excipients.
References
[1] GlobalData. (2023). KEPPRA (Levetiracetam) Market Analysis.
[2] U.S. Patent and Trademark Office. (2022). Patent filings related to KEPPRA formulations.
